中国组织工程研究
中國組織工程研究
중국조직공정연구
Journal of Clinical Rehabilitative Tissue Engineering Research
2014年
42期
6805-6810
,共6页
组织构建%组织工程%增殖性糖尿病视网膜病变%眼%安维汀(Avastin)%房水%细胞因子
組織構建%組織工程%增殖性糖尿病視網膜病變%眼%安維汀(Avastin)%房水%細胞因子
조직구건%조직공정%증식성당뇨병시망막병변%안%안유정(Avastin)%방수%세포인자
eye%retinal diseases%diabetic mel itus%aqueous humor%cytokines
背景:关于抑制血管生成药安维汀(Avastin)治疗增殖型糖尿病视网膜病变的机制研究大多数均局限在血管内皮生长因子本身,而结缔组织生长因子、血管增生抑制因子也在其疾病中扮演着重要的角色。<br> 目的:考察增殖性糖尿病视网膜病变玻璃体切割术前应用安维汀玻璃体腔注射前后房水细胞因子的变化。<br> 方法:选取增殖性糖尿病视网膜病变患者30例(30眼),采用随机数字表法分为3组,每组10例(10眼)。玻璃体切割组:直接行玻璃体切割手术;安维汀注射0.05 mL组:于玻璃体切割前7 d玻璃体腔注射0.05 mL安维汀(1.25 mg);安维汀注射0.1 mL组:于玻璃体切割前7 d玻璃体腔注射0.1 mL安维汀(2.5 mg)。分别于术中抽取少量房水,检查血管内皮生长因子、结缔组织生长因子及色素上皮衍生因子的表达变化。<br> 结果与结论:与玻璃体切割组比较,安维汀注射组房水中血管内皮生长因子含量降低,色素上皮衍生因子和结缔组织生长因子含量增高,并能抑制血管内皮生长因子的表达,差异有显著性意义;安维汀注射0.05 mL组与安维汀注射0.1 mL组相比,差异无显著性意义。结果说明玻璃体腔注射安维汀在增殖性糖尿病视网膜病变玻璃体切割前辅助应用可以减少与增殖相关的细胞因子的含量,同时增加了拮抗新生血管生长的细胞因子。
揹景:關于抑製血管生成藥安維汀(Avastin)治療增殖型糖尿病視網膜病變的機製研究大多數均跼限在血管內皮生長因子本身,而結締組織生長因子、血管增生抑製因子也在其疾病中扮縯著重要的角色。<br> 目的:攷察增殖性糖尿病視網膜病變玻璃體切割術前應用安維汀玻璃體腔註射前後房水細胞因子的變化。<br> 方法:選取增殖性糖尿病視網膜病變患者30例(30眼),採用隨機數字錶法分為3組,每組10例(10眼)。玻璃體切割組:直接行玻璃體切割手術;安維汀註射0.05 mL組:于玻璃體切割前7 d玻璃體腔註射0.05 mL安維汀(1.25 mg);安維汀註射0.1 mL組:于玻璃體切割前7 d玻璃體腔註射0.1 mL安維汀(2.5 mg)。分彆于術中抽取少量房水,檢查血管內皮生長因子、結締組織生長因子及色素上皮衍生因子的錶達變化。<br> 結果與結論:與玻璃體切割組比較,安維汀註射組房水中血管內皮生長因子含量降低,色素上皮衍生因子和結締組織生長因子含量增高,併能抑製血管內皮生長因子的錶達,差異有顯著性意義;安維汀註射0.05 mL組與安維汀註射0.1 mL組相比,差異無顯著性意義。結果說明玻璃體腔註射安維汀在增殖性糖尿病視網膜病變玻璃體切割前輔助應用可以減少與增殖相關的細胞因子的含量,同時增加瞭拮抗新生血管生長的細胞因子。
배경:관우억제혈관생성약안유정(Avastin)치료증식형당뇨병시망막병변적궤제연구대다수균국한재혈관내피생장인자본신,이결체조직생장인자、혈관증생억제인자야재기질병중분연착중요적각색。<br> 목적:고찰증식성당뇨병시망막병변파리체절할술전응용안유정파리체강주사전후방수세포인자적변화。<br> 방법:선취증식성당뇨병시망막병변환자30례(30안),채용수궤수자표법분위3조,매조10례(10안)。파리체절할조:직접행파리체절할수술;안유정주사0.05 mL조:우파리체절할전7 d파리체강주사0.05 mL안유정(1.25 mg);안유정주사0.1 mL조:우파리체절할전7 d파리체강주사0.1 mL안유정(2.5 mg)。분별우술중추취소량방수,검사혈관내피생장인자、결체조직생장인자급색소상피연생인자적표체변화。<br> 결과여결론:여파리체절할조비교,안유정주사조방수중혈관내피생장인자함량강저,색소상피연생인자화결체조직생장인자함량증고,병능억제혈관내피생장인자적표체,차이유현저성의의;안유정주사0.05 mL조여안유정주사0.1 mL조상비,차이무현저성의의。결과설명파리체강주사안유정재증식성당뇨병시망막병변파리체절할전보조응용가이감소여증식상관적세포인자적함량,동시증가료길항신생혈관생장적세포인자。
BACKGROUND:Studies on the inhibitory mechanism of Avastin for proliferative diabetic retinopathy are mostly confined to the vascular endothelial growth factor, while connective tissue growth factor and angiogenesis inhibitor also play an important role in the disease. <br> OBJECTIVE:To evaluate the changes of cytokines in the aqueous undergoing Avastin intravitreous injection or not prior to pars plana vitrectormy in the treatment of proliferative diabetic retinopathy. <br> METHODS:Thirty patients with proliferative diabetic retinopathy (30 eyes) were selected and randomly divided into groups A, B and C, each group containing 10 patients. Group A was treated with single pars plana vitrectormy;and group B and group C had 0.05 mL/1.25 mg and 0.1 mL/1.25 mg Avastin via intravitreous injection at 7 days before pars plana vitrectormy, respectively. Aqueous humor samples were col ected during pars plana vitrectormy. The levels of vascular endothelial growth factor, connective tissue growth factor and pigment epithelium-derived factor were assessed by using ELISA technique. <br> RESULTS AND CONCLUSION:The levels of connective tissue growth factor and pigment epithelium-derived factor in the aqueous humor of two Avastin injection groups were increased significantly compared to the group with single pars plana vitrectormy. However, the level of vascular endothelial growth factor was lower in the Avastin injection groups. In addition, there was no significant difference between two Avastin injection groups. These results reveal that intravitreous injection of Avastin assisted vitrectomy for proliferative diabetic retinopathy is more effective than single pars plana vitrectormy treatment. The underlying mechanisms may be that Avastin could inhibit the intraocular angiogenesis by not only reducing the secretion of some growth factors but also increasing the levels of anti-angiogenesis related cytokines.